The American drug authority FDA approves the Alzheimer's medicine donanemab, which is sold under the name Kisunla. It is an antibody that can partially slow down the development of the disease for patients in its early stages.
It is the second medicine of its kind on the market in the USA after last year's approval of lecanemab, which is sold under the name Leqembi and partially builds on a Swedish discovery.
The effect of both medicines is, however, modest, involving a braking effect measured in months. Kisunla, developed by the pharmaceutical giant Eli Lilly, slows down the disease by approximately seven months, according to studies.
Neither Leqembi nor Kisunla is currently approved in Europe.
Alzheimer's is an incurable dementia disease. Approximately 100,000 Swedes, almost all over 65 years old, live with the disease, according to the Brain Foundation.
